CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 2, 2006, Pages 207-212

  Hunt, Aoife ^a   Schönknecht, Peter ^a   Henze, Markus ^a   Toro, Pablo ^a   Haberkorn, Uwe ^a   Schröder, Johannes ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Aging associated cognitive decline; Alzheimer's disease; CSF tau protein; FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; TEMPORAL CORTEX;

EID: 33745907239     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.2.207     Document Type: Article

References (38)

1. Andreasen N, Vanmechelen E, Van de Voorde A, et al. 1998. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community follow up study. J Neurol Neurosurg Psychiatry, 64: 298-305.
2. Andreasen N, Vanmechelen E, Vanderstichele H, et al. 2003. Cerebrospinal fluid levels of total-tau, p-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand, 179(Suppl):47-51.
3. Arai H, Satoh-Nakagawa T, Higuchi M, et al. 1998. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett, 256:174-76.
4. Blennow K, Hampel H. 2003. CSF markers for incipient Alzheimer's disease. Lancet Neurol, 2:605-13.
5. Buerger K, Otto M, Teipel SJ et al. 2006. Dissocoation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging, 27:10-15.
6. Cabeza R, Nyberg L. 2000. Imaging cognition II. An empirical review of 275 PET and fMRI studies. J Cogn Neurosci, 12:1-47.
7. Chetelat G, Desgranges B, de la Sayette MD, et al. 2003. Mild Cognitive Impairment. Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology, 60:1374-7.
8. De Carli C. 2003. Mild cognitive impairment: clinical characterization and outcome. Lancet Neurol, 2:15-21.
9. De Leon MJ, Convit A, Wolf OT, et al. 2001. Prediction of cognitive decline in normal elderly subjects with 2-(18F) fluoro-2-deoxy-D-glucose/ positron-emission-tomography (FDG/PET). Proc Natl Acad Sci U S A, 98:10966-71.
10. Desgranges B, Baron JC, Lalevee C, et al. 2002. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain, 125: 1116-24.
11. Drzezga A, Lautenschlager N, Siebner H, et al. 2003. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging, 30:1104-13.
12. Elias MF, Beiser A, Wolf PA, et al. 2000. The preclinical phase of Alzheimer disease. A 22-year prospective study of the Framingham cohort. Arch Neurol, 57:808-13.
13. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini Mental State'. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res, 12:189-98.
14. Friston KJ, Holmes AP, Worsley KJ, et al. 1995. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp, 2:189-210.
15. Herholz K, Salmon E, Perani D, et al. 2002. Discrimination between Alzheimer Dementia and Controls by automated analysis of Multicenter FDG PET. Neuroimage, 17:302-16
16. Herukka SK, Hallikainen M, Soininen H, et al. 2005. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology, 64:1294-7.
17. Loeb C, Gandolfo C. 1983. Diagnostic evaluation of degenerative and vascular dementia. Stroke, 14:399-401.
18. Levy R. 1994. Aging-associated cognitive decline. Int Psychogeriatr, 6: 63-8.
19. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology, 34:939-65.
20. Nestor PJ, Fryer TD, Ikeda M, et al. 2003. Retrosplenial cortex (BA 29/ 30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci, 18:2663-7.
21. Pantel J, Schröder J, Schad LR, et al. 1997. Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Psychol Med, 27:221-9.
22. Pantel J, Schönknecht P, Essig M, et al. 2002. Progressive medial temporal lobe changes in Alzheimer's disease revealed by quantitative MRI - potential use for the monitoring of drug-related changes. Drug Dev Res, 56:51-6.
23. Pantel J, Kratz B, Essig M, et al. 2003 Parahippocampal volume deficits in subjects with aging-associated cognitive decline. Am J Psychiatry, 160:379-82.
24. Petersen CP, Doody R, Kurz A, et al. 2001. Current concepts in mild cognitive impairment. Arch Neurol, 58:1985-92.
25. Ritchie K, Arteron S, Touchon J. 2001. Classification criteria for mild cognitive impairment - a population-based validation study. Neurology, 56:37-42.
26. Schönknecht P, Pantel J, Hunt A, et al. 2003a. Tau protein phosphorylated at threonine 181 is increased in incipient and manifest Alzheimer's disease but not in vascular dementia. Neurosci Lett, 339:172-4.
27. Schönknecht P, Henze M, Hunt A, et al. 2003c. Hippocampal glucose metabolism is associated with cerebrospinal fluid estrogen levels in postmenopausal women with Alzheimer's Disease. Psychiatry Res, 124:125-7
28. Schönknecht P, Pantel J, Hartmann T, et al. 2003b. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res, 120:231-8.
29. Schönknecht P, Pantel J, Kaiser E, et al. 2004. Total and phospho-tau (Thr 181) CSF levels in patients with mild cognitive impairment and Alzheimer's disease. Polish J Old Age Psych, 1:185-92
30. Schönknecht P, Pantel J, Kruse A, et al. 2005. Prevalence and natural course of aging-associated cognitive decline in a population based sample of "young-old" subjects. Am J Psychiatry, 162:2071-7.
31. Schröder J, Buchsbaum MS, Shihabuddin L, et al. 2001. Patterns of cortical activity and memory performance in Alzheimer's disease. Biol Psychiatry, 49:426-36.
32. Schröder J, Kratz B, Pantel J et al. 1998. Prevalence of mild cognitive impairment in a community sample. J Neural Transm Suppl, 54: 51-9.
33. Schröder J, Pantel J, Ida N, et al. 1997. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry, 2:505-7.
34. Silverman DH, Small GW, Chang CY, et al. 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. J Am Med Assoc, 286:2110-7.
35. Skoog I, Vanmechelen E, Andreasson LA, et al. 1995. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegen, 4:433-42.
36. Talairach JA, Tournoux P 1988. Co-planar stereotaxic atlas of the human brain. Paris: Thieme.
37. Tapiola T, Lethovirta M, Ramberg J, et al. 1998. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology, 50:169-74.
38. Vandermeeren M, Mercken M, Vanmechelen E, et al. 1993. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem, 61:1828-34.